Hogervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F
Human Retrovirus Laboratory, University of Amsterdam, Netherlands.
J Infect Dis. 1995 Apr;171(4):811-21. doi: 10.1093/infdis/171.4.811.
To gain insight into determinants that define the duration of the asymptomatic period preceding AIDS, groups of long-term asymptomatic (LTA) person (> 7 years of follow-up) and slow and rapid progressors of human immunodeficiency virus infection were studied. LTAs had no clinical manifestations of AIDS or immunologic abnormalities in 7 years of follow-up. RNA copy numbers, gag- and env-specific, and neutralizing antibody titers in serum were determined 1 and 5 years after seroconversion or entry into the cohort. Early in infection, before immunologic markers or clinical manifestations allowed group discrimination, subjects who were later classified as LTAs had significantly less serum viral RNA than progressors. No significant increase in virus load was found in progressors, indicating that the initial load defines clinical outcome. In slow progressors, high virus load was associated with high p24-specific antibody titers, suggesting that delay of clinical manifestations of AIDS may be related to the presence of high levels of p24-specific but not V3-specific antibodies.
为深入了解决定艾滋病无症状期持续时间的因素,对长期无症状(LTA)人群(随访超过7年)以及人类免疫缺陷病毒感染的缓慢进展者和快速进展者进行了研究。长期无症状者在7年的随访中没有艾滋病的临床表现或免疫异常。在血清转化或进入队列后的第1年和第5年,测定血清中的RNA拷贝数、gag和env特异性以及中和抗体滴度。在感染早期,在免疫标志物或临床表现能够区分组别之前,后来被归类为长期无症状者的受试者血清病毒RNA明显低于进展者。进展者的病毒载量没有显著增加,这表明初始载量决定临床结局。在缓慢进展者中,高病毒载量与高p24特异性抗体滴度相关,这表明艾滋病临床表现的延迟可能与高水平的p24特异性抗体而非V3特异性抗体的存在有关。